Abstract：
Follicular lymphoma (FL) is the second most common non-Hodgkin lymphoma in Western countries after diffuse large B-cell lymphoma. Most patients with FL present with asymptomatic disease. Survival rates have been rising over time mainly due to advancing therapeutic strategiesA-51-year-old male with a history of well-controlled diabetes mellitus treated with insulin presented to the policlinic of hematology-medical oncology with worsening right inguinal lymphadenopathy for >3 months. He had no complaints of prolonged fever, night sweat, or weight loss. Initial physical examination revealed a healthy male with bulky right inguinal lymphadenopathy. The patient was then referred to a surgeon, and excisional biopsy of the enlarged right inguinal lymph nodes was performed. Therefore, stage II bulky symptomatic low-grade FL was established. We administered chemoimmunotherapy with rituximab and bendamustine every 3 weeks for six cycles. The patient tolerated the treatment well and completed six cycles of chemoimmunotherapy, and the follow-up FDG PET/CT showed complete remission of the disease.The patient achieved complete remission after series of chemoimmunotherapy with Bendamustine-Rituximab. Future assessment is still required for this patient to ensure the remission status of the lymphoma.
摘要：
滤泡性淋巴瘤（FL）是西方国家仅次于弥漫性大B细胞淋巴瘤的第二大最常见的非霍奇金淋巴瘤。大多数FL患者表现为无症状疾病。随着时间的推移，生存率一直在上升，主要是由于治疗策略的推进。一名51岁的男性，有良好的糖尿病史，接受胰岛素治疗，出现在血液学-医学肿瘤学领域，右腹股沟淋巴结病恶化>3个月。他没有长期发烧的抱怨，盗汗,或减肥。最初的体格检查显示，一名健康的男性患有巨大的右腹股沟淋巴结肿大。然后病人被转诊给外科医生，并对右侧腹股沟肿大的淋巴结进行了切除活检。因此,建立了II期大体积症状低度FL。我们每3周用利妥昔单抗和苯达莫司汀进行化学免疫疗法，共六个周期。患者耐受良好，完成了6个周期的化学免疫治疗，随访FDGPET/CT显示病情完全缓解。患者在使用苯达莫司汀-利妥昔单抗进行一系列化学免疫疗法后达到完全缓解。仍需要对该患者进行未来评估，以确保淋巴瘤的缓解状态。
